Tharimmune Secures European Patent for Innovative Cancer Therapy Platform

Tharimmune, Inc., a clinical-stage biotechnology company, announced the European Patent Office's intention to grant a patent for its biodegradable polymeric nanoparticles. These are developed for medical applications, specifically enhancing the delivery of therapeutic antibodies and peptides, crucial in cancer therapies. This technology counters challenges of enzymatic degradation and poor systemic circulation, improving drug efficacy by extending their half-life in the bloodstream and minimizing side effects.

The new patent covers nanoparticle design and application, aimed at penetrating biological barriers and directly delivering drugs to disease sites. While awaiting a similar U.S. patent, this milestone supports Tharimmune's strategy to advance its therapeutic pipeline, including collaborations for antibody conjugations.

Randy Milby, CEO of Tharimmune, highlighted the platform's potential to tackle stability and absorption issues inherent in molecularly targeted therapies. The patent complements existing efforts, such as colonic targeting via a partnership with Intract Pharma.